ArticleTranslational neurodegeneration2023
Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson's disease.
Article in Translational neurodegeneration, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 40 citations in OpenAlex.
- Effects of the novel phosphodiesterase 9 inhibitor irsenontrine on CSF proteomics profile in AβAlzheimer's research & therapy · 2026Trial
- Serum aromatic l-amino acid decarboxylase activity as a biomarker for prodromal and manifest Parkinson's disease.EBioMedicine · 2026Article
- Advances in biomarkers for Parkinson's disease: from molecular pathology to precision diagnostics.Journal of Zhejiang University. Science. B · 2026Review
- The complement C3-microglial axis in depression of Parkinson's disease: from mechanism to therapeutic intervention.EBioMedicine · 2026Article
- From phenotype to biology: a multi-modal roadmap of biofluid, tissue, imaging, and digital biomarkers in Parkinson's disease.Translational neurodegeneration · 2026Review
- Body Fluid-based Biomarkers for Cognitive Impairment in Parkinson's Disease.Annals of neurosciences · 2026Review
- Identification, Screening and Mechanism Analysis of Anti-Parkinson's Disease Peptides fromMarine drugs · 2026Article
- A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders.Nature medicine · 2026Article
- A monoclonal antibody-based immunoassay reinforces DOPA decarboxylase in cerebrospinal fluid as a diagnostic biomarker for Parkinson's disease with potential prognostic value.Journal of Parkinson's disease · 2026Article
- High Cerebrospinal DOPA Decarboxylase Level Predicts Cognitive Decline in Parkinson's Disease.Movement disorders clinical practice · 2026Article
- Integrative Transcriptomic Analysis Identifies Novel Mitochondrial Gene Targets in Parkinson's Disease.Molecular neurobiology · 2026Article
- Development and validation of a novel panel of CSF biomarkers for Alzheimer's disease.Alzheimer's research & therapy · 2026Article
- Machine learning analysis of population-wide plasma proteins identifies hormonal biomarkers of Parkinson's disease.Frontiers in aging neuroscience · 2026Article
- Identification of a robust multitarget protein panel for Parkinson's disease via absolute quantification and large-scale external replication.Brain communications · 2026Article
- Orthogonal validation of PD Biomarkers: Multi-platform proteomics profiling of CSF, Plasma, and Urine confirms DDC as a consistent candidate.medRxiv : the preprint server for health sciences · 2025Article
- Micro- and nanoscale biosensing technologies for early diagnosis of Parkinson's disease.Mikrochimica acta · 2025Review
- Identifying Immune Response Protein Biomarkers in Parkinson's-Related Cognitive Impairment and Depression.Molecular neurobiology · 2025Article
- Differentiating Progressive Supranuclear Palsy and Corticobasal Syndrome: Insights from Cerebrospinal Fluid Biomarkers-A Narrative Review.Medicina (Kaunas, Lithuania) · 2025Review
- Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment.Nature communications · 2025Article
- Exploring dopa decarboxylase as an ideal biomarker in Parkinson's disease with focus on regulatory mechanisms, cofactor influences, and metabolic implications.npj biomedical innovations · 2025Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundThere is a need for biomarkers to support an accurate diagnosis of Parkinson's disease (PD). Cerebrospinal fluid (CSF) has been a successful biofluid for finding neurodegenerative biomarkers, and modern highly sensitive multiplexing methods offer the possibility to perform discovery studies. Using a large-scale multiplex proximity extension assay (PEA) approach, we aimed to discover novel diagnostic protein biomarkers allowing accurate discrimination of PD from both controls and atypical Parkinsonian disorders (APD).
methodsCSF from patients with PD, corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), multiple system atrophy and controls, were analysed with Olink PEA panels. Three cohorts were used in this study, comprising 192, 88 and 36 cases, respectively. All samples were run on the Cardiovascular II, Oncology II and Metabolism PEA panels.
resultsOur analysis revealed that 26 and 39 proteins were differentially expressed in the CSF of test and validation PD cohorts, respectively, compared to controls. Among them, 6 proteins were changed in both cohorts. Midkine (MK) was increased in PD with the strongest effect size and results were validated with ELISA. Another most increased protein in PD, DOPA decarboxylase (DDC), which catalyses the decarboxylation of DOPA (L-3,4-dihydroxyphenylalanine) to dopamine, was strongly correlated with dopaminergic treatment. Moreover, Kallikrein 10 was specifically changed in APD compared with both PD and controls, but unchanged between PD and controls. Wnt inhibitory factor 1 was consistently downregulated in CBS and PSP patients in two independent cohorts.
conclusionsUsing the large-scale PEA approach, we have identified potential novel PD diagnostic biomarkers, most notably MK and DDC, in the CSF of PD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.